Rapid Micro Biosystems Q1 FY26 net loss widens to $14.3 million; revenue rises 11.1% to $8 million
Rapid Micro Biosystems, Inc. Class A
Rapid Micro Biosystems, Inc. Class A RPID | 0.00 |
- Rapid Micro Biosystems posted Q1 2026 revenue of $8 million, up 11% from a year earlier, while net loss widened to $14.3 million.
- Net loss per share deepened to $0.31; gross margin slipped 1 percentage point to 4.6%.
- Product revenue rose 36% to $5.6 million, while service revenue fell 21.9% to $2.4 million on lower validation activity.
- Recurring revenue climbed 27.7% to $5.1 million, making up 63% of total revenue; six Growth Direct systems were placed versus three a year earlier.
- Rapid Micro Biosystems reaffirmed 2026 revenue outlook of $37 million-$41 million, including 30-38 Growth Direct placements, and said it executed a Services Agreement advancing its strategic collaboration with MilliporeSigma.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rapid Micro Biosystems Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605131625PRIMZONEFULLFEED9719819) on May 13, 2026, and is solely responsible for the information contained therein.